Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
(Last updated 17MAR2022)
A Phase II Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer. (PANTHER) NCT05024097. Click here to enquire about this study.
Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT). NCT04984343 Click here to enquire about this study.
The DIGNITY Study (De-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you). NCT05134779 Click here to enquire about this study.
A Multi-Center study of Androgen Suppression with abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic body radiotherapy (ASCLEPIuS): A phase I/2 trial in high risk or node positive prostate cancer - (SPONSOR - University of Michigan) Click here to enquire about this study.
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks (SHORTER). (NCT04422132) Click here to enquire about this study.
NYP- WELCOME trial (Weill Cornell Medicine Employees) Click here to sign up for this study.
Prone partial breast irradiation (PBI): Prospective randomized controlled non-inferiority trial to compare radiation fibrosis with five versus three fractions (NCT02755896) Click here to enquire about this study.
Accelerated Radiation Therapy (ART) To the Breast and Nodal Stations after Neo-Adjuvant Chemotherapy and Surgery: A Feasibility Study (NCT02917421). Click here to enquire about this study.
Pembrolizumab and Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients (NCT03449238). Click here to enquire about this study.
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) (NCT03663218). Click here to enquire about this study.
Prospective Randomized study of Accelerated Radiation Therapy (PRART) (NCT04175210). Click here to enquire about this study.
Converting HR+ Breast Cancer Into an Individualized Vaccine (NCT03804944). Click here to enquire about this study.
Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study. NCT04371913. Click here to enquire about this study. Click here to enquire about this study.
Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer (PSMA SBRT-SIB) NCT04402151. Click here to enquire about this study.
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer NCT04563507 . Click here to enquire about this study.
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer NCT04220983. Click here to enquire about this study.
***************************************************************************************************
Last Updated 17MAR2022
Prospective phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer. NCT03621644.
Effect of radiotherapy variables on circulating effectors of immune response and local microbiome (NCT03383107).
Radiation and immune checkpoints blockade in metastatic NSCLC (BMS # CA209-632) (NCT03168464).
RTOG0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only RT (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy (NCT00567580)
An Open-Label Multicenter Phase 1b Study of E7046 in Combination with Radiotherapy/ Chemo radiotherapy (RT/CRT) in preoperative treatment of Subjects with Rectum Cancer (NCT03152370)
NRG GU003 - A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT) (NCT03274687)
***************************************************************************************************
last updated 17MAR2022
A Phase II randomized controlled trial of PD-1/PDL-1 axis blockade versus PD-1/PDL-1 axis blockade plus radiotherapy in metastatic genitourinary (renal/urothelial) malignancies (NCT03115801)
MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer (SIBRT) (NCT03664193)
ISABR STUDY: A Multi-Site Randomized Phase I/II Study of Stereotactic Ablative Body Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early- Stage Non-Small Cell Lung Cancer
Randomized trial of image-guided stereotactic radiation therapy (IG-SRT) in prostate cancer (NCT02911922)
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies (NCT02383212)
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer (NCT02538471)
Phase I/II study of TLR7 agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients with Chest Wall Recurrence or Skin Metastases (NCT01421017)
